Nogo-66 receptor 1 complex (NgR1 complex) (NgR1 complex)

The Nogo-66 receptor 1 complex (NgR1 complex) is a tripartite signaling assembly on the neuronal membrane that mediates the inhibition of axonal growth in the central nervous system (CNS) [1]. It is primarily composed of the ligand-binding subunit NgR1 (RTN4R), a signal-transducing co-receptor such as the p75 neurotrophin receptor (p75NTR) or TROY, and the transmembrane protein LINGO-1 [2, 3]. This complex is activated by myelin-associated inhibitors (MAIs) including Nogo-A, myelin-associated glycoprotein (MAG), and oligodendrocyte myelin glycoprotein (OMgp), which are exposed following CNS injury or demyelination [1]. Upon ligand binding, the complex triggers the RhoA/ROCK signaling pathway, leading to growth cone collapse and stabilization of the actin cytoskeleton, which prevents damaged axons from regrowing [1, 2]. Because this pathway is a major impediment to recovery in conditions like spinal cord injury, stroke, and multiple sclerosis, it is a high-priority therapeutic target [4, 5]. Experimental interventions, such as the decoy receptor AXER-204 and the anti-LINGO-1 antibody opicinumab, aim to block this inhibitory signaling to facilitate neuroregeneration and functional repair [4, 5]. Sources: [1] He, Z., & Koprivica, V. (2004). "The Nogo signaling pathway for regeneration block." Annual Review of Neuroscience. [2] Mi, S., et al. (2004). "LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex." Nature Neuroscience. [3] Wang, X., et al. (2002). "p75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp." Nature. [4] ReNetX Bio. "AXER-204 for Spinal Cord Injury." [5] Biogen. "Opicinumab (Anti-LINGO-1) in Multiple Sclerosis."

Other names

Nogo receptor complexNgR1/p75/LINGO-1 complexRTN4R complexNogo-66 receptor complexNgR1/TROY/LINGO-1 complex

Antagonism of the Nogo-66 receptor 1 complex to block inhibitory signaling from myelin-associated proteins, thereby promoting axonal regeneration and remyelination through the inhibition of the RhoA pathway.